So far we know the low eGFR (Stage 3) people benefitted from ABET significantly (lower MACE) compared to placebo, but sample size low.  What we don't know is  if /how much ABET improved the eGFR of this particular population...  if it took a Stage 3 kidney patient way up the safety ladder, while reducing MACE, that combination could catch the FDA eye for breakthrough status.

There is some suggested link between renal decline and cognitive decline, so if they decided to show that data live to the medical community as part of the CTAD data,  because it is good, and they see potential for a bigger splash... that could get the market's attention I suppose. 

But like many here, I think FDA letter , or announcement of a partnership or buyer, are the first thing that will move the market... I think they are twice bitten, thrice shy.